You are here: Industry Insights > Sandoz

News List

Sandoz seeks EMA approval for EirGenix’s trastuzumab biosimilar Pharmaceutical-Business-Review
December 24, 2021
Trastuzumab is a monoclonal antibody intended to treat human epidermal growth factor receptor 2 positive (HER2-positive) breast and metastatic gastric cancers.
Sandoz Announces Plans to Further Strengthen its Antibiotics Manufacturing Setup in Europe americanpharmaceuticalreview
May 19, 2021
Sandoz, a Novartis division has announced plans to further strengthen its European antibiotics manufacturing network by further expanding production capabilities in Kundl, Austria and in Palafolls, Spain.
US Supreme Court Denies Sandoz Petition to Review Biosimilar Erelzi® Case americanpharmaceuticalreview
May 19, 2021
Sandoz has announced that the US Supreme Court has denied its petition to review the Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi® (etanercept-szzs) for reference medicine Enbrel®* (etanercept).
ANI Acquires Branded Products Portfolio from Sandoz contractpharma
April 08, 2021
ANI Pharmaceuticals Inc. has acquired the new drug applications (NDAs) for Oxistat Lotion, Veregen Ointment, and Pandel Cream and the abbreviated new drug application (ANDA) for ApexiCon E Cream from Sandoz Inc. Pandel Cream will be transitioned ...
Sandoz to acquire GlaxoSmithKline’s cephalosporin antibiotics business pharmaceutical-business-review
February 20, 2021
Global leader in antibiotics and a division of Swiss multinational pharma company Novartis, Germany-based Sandoz has signed a contract to acquire GlaxoSmithKline’s (GSK) cephalosporin antibiotics.
Sandoz Announces Joint Investment with Austrian Government contractpharma
August 04, 2020
Aims to drive long-term competitiveness of European production for key antibiotics in Europe.
Sandoz partners with Austria to boost antibiotics production pharmaceutical-technology
July 29, 2020
Swiss pharmaceutical company Novartis unit Sandoz has partnered with the Austrian Government to boost integrated antibiotics production in Europe.
Sandoz and Austrian government to invest in European antibiotic manufacturing europeanpharmaceuticalreview
July 28, 2020
Sandoz plans to invest €150 million and the Austrian government €50 million into integrated antibiotic manufacturing operations at Kundl.
Novartis offers non-profit medicines portfolio for Covid-19 pharmaceutical-technology
July 17, 2020
Swiss pharmaceutical giant Novartis has launched a not-for-profit medicines portfolio to help treat Covid-19 symptoms in patients in low-income and lower-middle-income countries.
Federal Circuit Rules Upholds Lower Court Ruling in Biosimilar Erelzi Case americanpharmaceuticalreview
July 13, 2020
Sandoz, a Novartis division, announced the US Court of Appeals for the Federal District has ruled against Sandoz in patent litigation concerning the Sandoz biosimilar Erelzi® (etanercept-szzs) for reference medicine Enbrel® (etanercept).

Previous page 1 2 3 4 5 6 7 8 Next page